Apr 26th 2012 - Edison Investment Research today published a report on Zeltia entitled "US Plans On Track". In summary, the report says:
Zeltia’s Pharma Mar subsidiary has received a second $25m milestone payment from Yondelis (trabectedin) ex-Europe partner Janssen (J&J). This follows the December 2011 receipt of $25m paid on agreement of the new US development plan. A further $60m of milestones may fall due in 2013/2015, in addition to the economics agreed at the time of the original license. Zeltia is also approaching key pipeline catalysts, with an interim analysis of the ADMYRE study of Aplidin in relapsed/refractory multiple myeloma expected soon, an interim analysis of the Phase II PM01183 trial in resistant ovarian cancer and results of its 309-pt Phase II study of Nypta (tideglusib) in Alzheimer’s disease, both due at the end of the year.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »